News & Views | Published:


Resolving atherosclerosis and Alzheimer disease

Nature Reviews Cardiologyvolume 16pages259260 (2019) | Download Citation

Nonresolving inflammation underpins several prevalent diseases, including atherosclerosis and Alzheimer disease. The resolution of inflammation is an active process that tempers pro-inflammatory pathways and promotes tissue repair. Understanding the mechanisms that boost endogenous resolution is important for the design of new treatment strategies for nonresolving diseases.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Yin, C. et al. ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Nat. Med. 25, 496–506 (2019).

  2. 2.

    Serhan, C. N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92–101 (2014).

  3. 3.

    Chiang, N. et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484, 524–528 (2012).

  4. 4.

    Fredman, G. et al. Self-limited versus delayed resolution of acute inflammation: temporal regulation of pro-resolving mediators and microRNA. Sci. Rep. 2, 639 (2012).

  5. 5.

    Fredman, G. et al. An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat. Commun. 7, 12859 (2016).

  6. 6.

    Tabas, I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10, 36–46 (2010).

  7. 7.

    Viola, J. R. et al. Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice. Circ. Res. 119, 1030–1038 (2016).

  8. 8.

    Wang, X. et al. Resolution of inflammation is altered in Alzheimer’s disease. Alzheimers Dement. 11, 40–50 (2015).

  9. 9.

    Mahley, R. W. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J. Mol. Med. 94, 739–746 (2016).

  10. 10.

    Knouff, C. et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J. Clin. Invest. 103, 1579–1586 (1999).

Download references


The author is supported by the NIH (grants HL119587 and HL141127).

Author information


  1. Department of Molecular and Cellular Physiology, Albany Medical College, Albany, NY, USA

    • Gabrielle Fredman


  1. Search for Gabrielle Fredman in:

Competing interests

The author declares no competing interests.

Corresponding author

Correspondence to Gabrielle Fredman.

About this article

Publication history


Issue Date


Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing